secwatch.observer — SEC 8-K summary
======================================

Issuer:     FEMASYS INC (FEMY)
CIK:        0001339005
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001140361-23-038917
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Femasys Q2 net loss $2.9M; starts FemBloc pivotal trial; appoints COO
---------------------------------------------------------------------

- Q2 net loss $2.9M ($0.22 EPS), revenue $320K (+$17K YoY) from first international sales of $58K.
- Cash $10.7M at June 30; expected to fund operations into Q2 2024.
- Patient enrollment commenced in FINALE pivotal trial for FemBloc permanent birth control after FDA IDE approval.
- Daniel Currie appointed COO with base salary $389K and 40% bonus target.
- Received three Health Canada approvals for FemaSeed, FemCerv, FemCath in Q2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339005/000114036123038917/0001140361-23-038917-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339005/000114036123038917/brhc20057313_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-038917

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer